Efficacy, Safety, and Durability of Brolucizumab: An 8-Month Post-Marketing Surveillance Analysis

IMPORTANCE: Brolucizumab (Beovu(®)) is an anti-vascular endothelial growth factor (anti-VEGF) agent approved for the treatment of neovascular age-related macular degeneration (nvAMD). Brolucizumab was marketed for its noninferiority to aflibercept and its potential for greater durability. However, p...

Descripción completa

Detalles Bibliográficos
Autores principales: Saba, Nicholas J, Walter, Scott D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518423/
https://www.ncbi.nlm.nih.gov/pubmed/37753246
http://dx.doi.org/10.2147/OPTH.S425709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518423/
https://www.ncbi.nlm.nih.gov/pubmed/37753246
http://dx.doi.org/10.2147/OPTH.S425709

Ejemplares similares